The combination of venetoclax and quercetin exerts a cytotoxic effect on acute myeloid leukemia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
The combination of venetoclax and quercetin exerts a cytotoxic effect on acute myeloid leukemia ; volume:14 ; number:1 ; day:2 ; month:11 ; year:2024 ; pages:1-12 ; date:12.2024
Scientific reports ; 14, Heft 1 (2.11.2024), 1-12, 12.2024
- Creator
-
Kawakatsu, Renshi
Tadagaki, Kenjiro
Yamasaki, Kenta
Kuwahara, Yasumichi
Nakada, Shinichiro
Yoshida, Tatsushi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-78221-9
- URN
-
urn:nbn:de:101:1-2501212127272.140819668257
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kawakatsu, Renshi
- Tadagaki, Kenjiro
- Yamasaki, Kenta
- Kuwahara, Yasumichi
- Nakada, Shinichiro
- Yoshida, Tatsushi
- SpringerLink (Online service)
Other Objects (12)
Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points
Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy
Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points
Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy
Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points